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Introduction
Fungal infections, in particular candidemia, are a growing 
problem in immunocompetent patients [1]. Despite 
several guidelines, concern exists on the value of evidence 
supporting recommendations for the optimal treatment 
of candidemia in non-neutropenic adult patients [1,2].
In the midst of this controversy a critical reappraisal of 
the 2009 Infectious Diseases Society of America (IDSA) 
guidelines is appropriate [1]. Although many relevant 
aspects of the guidelines are thoroughly discussed, there 
are three topics that deserve a closer look: the weight and 
quality of the evidence; the evidence of eﬃ   cacy; and the 
evidence of amphotericin-B (AmB)-induced renal failure.
What is recommended by the 2009 IDSA 
guidelines?
In 2009, IDSA updated their 2004 guidelines (Table 1) 
[1,2]. Th  e primary recommendation for treatment of 
candidemia in non-neutropenic patients was adminis-
tration of ﬂ  uconazole or an echinocandin. Th  e  alternative 
approach was administration of lipid formulation (LF)-
AmB, AmB-deoxycholate (AmB-d) or voriconazole. Th  e 
recommendation for echinocandins was extended to 
patients with moderately severe to severe illness or with 
recent azole exposure.
A critical review of the evidence
Th   e 2009 IDSA guidelines [1] represent a marked change 
in the recommended therapeutic approach, and is not 
supported by the eﬃ   cacy of the diﬀ  erent antifungals. In 
all nine clinical trials, AmB-d and LF-AmB were never 
inferior to any comparator and two recent meta-analyses 
showed the same results [3,4]. Th   e use of AmB-d and LF-
AmB are supported by very solid data from well designed 
clinical trials and that have consequently been twice 
graded A-I [1]. Moreover, echinocandins are not suitable 
for the treatment of endophtalmitis, meningitis and 
endocarditis [5] whilst AmB remains the drug of choice.
Th  erefore, even though not explicit in the guidelines, 
the change is probably related to a possible advantage of 
echinochandins and the perceived renal dysfunction 
associated with AmB. In fact, the 2009 IDSA guidelines 
[1] attribute to AmB-d therapy a high risk of acute renal 
failure (ARF) and mortality.
The new evidence
A recent study from Reboli and colleagues [6] suggests 
that anidulafungin might be superior to ﬂ  uconazole as 
primary therapy for candidemia in non-neutropenic 
patients (75.6% success with anidul    afungin compared to 
60.2% with ﬂ   uconazole). However, in a noninferiority 
trial, only noninferiority can be demonstrated and any 
beneﬁ  t of the new treatment should be interpreted with 
great caution [7] and only be based on other advantages, 
such as safety, convenience and cost [8]. Besides, the 
evaluation of the primary end-point was made at the end 
of intravenous therapy, after a median of 14 days of 
anidulafungin against only 11 days of ﬂ  uconazole.  In 
addition, more patients in the anidulafungin group had 
their central venous catheter removed than in the 
ﬂ   uconazole arm (96% versus 89%). Consequently, as 
Sobel and Revankar wrote in an editorial [9], 
anidulafungin was, at best, noninferior in comparison to 
ﬂ  uconazole.
The myths on nephrotoxicity
Th   e change of the positioning of AmB preparations in the 
2009 guidelines [1,2] seems to be supported by the 
nephrotoxicity ﬁ  ndings of two studies, one showing that 
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and the other that AmB-d-induced nephrotoxicity is 
asso  ciated with a 6.6-fold increased risk of death [11] 
(Table 2).
Th  e ﬁ  rst study is a review about AmB nephrotoxicity 
[10]; in this review, the author cited another study 
published in 1999 [12] where those ﬁ  ndings  were 
presented. However, patients included in this retro  spec-
tive analysis were markedly immunosupressed, received 
concomitantly nephrotoxic agents, and received long 
courses of AmB (20.4 days) for sus  pected or proven 
aspergillosis, not invasive candidiasis. Accordingly, these 
ﬁ   ndings cannot be extrapolated to non-neutropenic 
patients with candidemia.
Th  e second study [11] is also a retrospective analysis 
published in 2001, using data from 707 admissions of 551 
patients treated with AmB-d. However, the inclusion of 
the same patient several times constitutes a major vio  la-
tion of the assumptions necessary to compare groups 
with the statistical methods used. Roughly, 30% of these 
admissions were complicated with ARF. Th  e average 
highest creatinine in this group was 3.3 ± 1.3 mg/dL, 
whereas in those without ARF it was 1.6 ± 0.7 mg/dL 
(P  <  0.0001). Th  e mortality rate in the admissions 
complicated with ARF was 54.2% and in those without 
ARF it was only 16% (odds ratio for death, 6.6). From 
these data, it is diﬃ   cult to envisage that patients with a 
mean increase in creatinine of 1.7 mg/dL had a 6.6-fold 
increased risk of death.
Besides, as we have already pointed out, AmB was 
never inferior to any comparator in six randomised 
controlled trials with non-neutropenic adult patients 
with candidemia [3,4]. If AmB-induced nephrotoxicity 
was so common and has such a detrimental eﬀ  ect on 
prognosis, it would be expected that this ﬁ  nding would 
have a negative eﬀ  ect on mortality.
Should we still use AmB-d?
Even though AmB-d is an old drug, it is still regarded as 
one of the drugs of choice for treatment of 
Table 1. Infectious Disease Society of America guidelines for the treatment of candidemia in non-neutropenic adult 
patients [1,2]
 2004  2009
Recommended therapy  AmB-d 0.6 to 1 mg/kg/day  Echinochandina: Caspofungin 50 mg/day (70 mg fi  rst dose)
  Fluconazole 400 to 800 mg/day  Anidulafungin 100 mg/day (200 mg fi  rst dose)
  Caspofungin 50 mg/day (70 mg fi  rst dose)  Micafungin 100 mg/day
    Fluconazol 6 mg/kg/day (12 mg/kg fi  rst dose)
Alternative therapy  AmB-d 0.7 mg/kg/day + Fluconazol 800 mg/day   LF-AmB 3 to 5 mg/kg/day
  (4 to 7 days, then Fluconazol 800 mg/day)  AmB-d 0.5 to 1 mg/kg
    Voriconazol 3 mg/kg bid (6 mg/kg fi  rst two doses)
Duration of therapy  At least 14 days after last positive blood culture  At least 14 days after last positive blood culture
Other recommendations  Removal of central venous catheter  Removal of central venous catheter
  Ophthalmological evaluation  Ophthalmological evaluation
aAn echinochandin was also recommended in moderate to severe infection or with recent azole exposure. AmB-d, Amphotericin-B deoxycholate; LF-AmB, lipid 
formulation Amphotericin-B.
Table 2. Amphotericin-B nephrotoxicity; data cited in 2009 Infectious Disease Society of America guidelines [1]
 Wingard  et al. [12]  Bates et al. [11]
Year of publication  1999  2001
Data collection  Jan 1991 to Dec 1993  May 1993 to Apr 1997
Inclusion criteria  1. Allogeneic BMT  Not patients but number of admissions; at least
  2. Autologous BMT  156 repeated measurements; major violation of the
  3. Solid organ transplantation  assumptions of statistical methods used
  4. Immunosuppressive conditions not related to 
      transplantation
Infection Aspergillosis  Unknown
Duration of AmB (days)  20.4  14.8
AmB cumulative dose (g)  Unknown  0.93
AmB daily dose (mg/kg)  Unknown  Unknown
Concomitant nephrotoxic agents  87%  Collected (not given)
Risk of death  HD >3×  ARF >6.6×
AmB, Amphotericin-B; ARF, acute renal failure defi  ned as a 50% increase in the baseline creatinine level, with a peak of >2.0 mg/dL; BMT, bone marrow transplant; HD, 
haemodialysis.
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therapy of febrile neutropenia. A Cochrane review 
published in 2000, but left unchanged after reassessments 
in 2007 and in 2009, provides support for this practice 
[13]. Th  at is probably because AmB-d remains the 
antifungal with the most rapid time-kill rate and the 
largest post-antifungal eﬀ  ect [14] and with eﬃ   cacy that 
increases with its concen  tra  tion [15]. LF-AmB could 
present a better safety proﬁ  le, but its cost constitutes a 
major limitation to its routine use. In addition, there are 
no solid data to support any beneﬁ  t from LF-AmB in 
comparison to AmB-d if administered with correct 
pre-medication.
Conclusion
Careful assessment of published data on the treatment of 
candidemia in non-neutropenic patients showed similar 
eﬃ     cacy between AmB preparations, ﬂ  uconazole  and 
echino chandins.  Th   e choice of ﬁ  rst line therapy should be 
based on individual risk factors, patterns of Candida 
susceptibility, clinical experience, as well as local availa-
bility of the diﬀ  erent drugs and their costs.
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